Challenges
Datasets
Workspaces
Papers
Discussions
Leaderboard
Log inSign up
Challenges
Datasets
Workspaces
Papers
Discussions
Leaderboard
Blog
Job Board
Q3AS

© 2026 Aqora Quantum S.A.S.

TermsPrivacyLegal Notice

Discover Computing

Quantum–classical hybrid learning framework for molecular property prediction and molecule optimization in drug discovery

S. Rama Sree, Medepalli Sandhya, A. Jayanthi, Venkateswararao Pulipati, Dr.M.Varaprasad Rao, Dasaka V. S. S. Subrahmanyam

Published Jun 21, 2026• 0 citations
Publisher

Abstract

Finding drug-like molecules is a time- and money-consuming task that requires virtual screening techniques capable of accurately representing non-linear intermolecular relationships. Classical ML models usually consider molecular graphs or SMILES sequences, but cannot jointly exploit both structural and sequential information, let alone simultaneously. Of greater importance, numerous deep learning methods are hindered by poor generalisation, black-box predictions, and inadequate interpretability, reducing their feasibility for application in real-life drug discovery pipelines. In this paper, we present QDrugDiscoverAI, a hybrid quantum–classical deep learning framework for predicting molecular properties and optimising molecules to overcome these challenges. We present a framework for multimodal molecular representation learning that combines graph attention networks and transformer-based sequence encoders with variational quantum circuits to increase expressive capacity within a single architecture. It implements a dual-stream representation-learning mechanism with a multimodal feature fusion layer. It includes an explainability module that uses attention weights and SHAP values to identify substructures that contribute to model predictions and enhance interpretability. Moreover, QDrugDiscoverAI also includes a quantum–assisted reinforcement-learning module for a molecule-optimisation workflow, enabling more efficient exploration of the chemical design space while leveraging the controllability of quantum simulation. The experiments on three benchmark datasets, i.e., Lipophilicity, HIV, and BBBP, show improvements of 12.4%, 9.6%, and 11.1% in accuracy, AUC, and F1-score, respectively, over the matched classical and unimodal baselines. Quantitative evaluation of quantum components and fusion strategies is also conducted through ablation studies to demonstrate their roles further. In summary, the framework proposed serves as a systematic integration of interpretable hybrid learning, showing one way it could be organised to become increasingly efficient, and demonstrating the advantage of using quantum-simulated components to enhance classical deep learning models for exploration and predictive performance in drug discovery workflows. The implementation code and supporting scripts for the proposed QDrugDiscoverAI framework are publicly available at: https://github.com/Sripada-RamaSree/QuantumDrugAI

DOI
10.1007/s10791-026-10240-8

Related papers

A Hybrid Quantum-Classical Machine Learning Framework for Accelerated Drug Discovery

Sriramadasu Sri Sainadh, Saigeetha S.B., Jeeru Bharath Reddy +4 more

The pharmaceutical industry faces mounting challenges in drug discovery, where exploring a chemical space exceeding 10 60 possible compounds remains computationally prohibitive. Traditional in-silico screening approaches struggle to capture the quantum mechanical interactions that determine molecular behavior. To overcome these limitations, this study introduces a hybrid quantum–classical machine learning framework that uniquely integrates molecular graph theory with quantum-enhanced learning for accelerated drug discovery. Using the QM9 benchmark dataset containing 133,885 molecules of low-to-medium structural complexity, we extract Laplacian eigenvalue spectra as topological descriptors that preserve both connectivity and electronic information. These features are jointly processed by Random Forest (RF), Support Vector Machine (SVM), and a Variational Quantum Classifier (VQC) in a weighted ensemble architecture designed for balanced generalization. The Quantum Graph Neural Network (QGNN) component achieves 97.5% accuracy, while the hybrid ensemble attains 100.0% accuracy, confirming strong predictive reliability. Although quantum training requires roughly 3.2× longer computation, it captures high-dimensional correlations that classical methods overlook. Overall, the proposed framework bridges the gap between theoretical quantum computing and practical pharmaceutical modeling, providing a scalable, physics-inspired pathway toward intelligent molecular screening and next-generation drug discovery systems.

Procedia Computer Science•Jan 1, 2026•0 citations

Hybrid Quantum-Classical Neural Networks for Molecular Property Prediction from SMILES

Sergey M. Gushanskiy, Viktor Potapov, Maxim Polenov

The prediction of molecular properties from SMILES strings is a cornerstone of modern drug discovery and materials science, yet traditional computational methods often face a trade-off between accuracy and speed. This paper presents a comprehensive hybrid quantum-classical architecture that synergistically combines a Bidirectional Long Short-Term Memory (BiLSTM) network with a variational quantum circuit (VQC) to perform multi-task regression on molecular properties. Our system introduces a novel quantum feature layer, implemented in PennyLane and integrated with PyTorch, which employs data reuploading and configurable entanglement patterns (linear, full, pairwise) to generate expressive quantum descriptors. These descriptors are concatenated with classical features and fed into a regression head, enabling the simultaneous prediction of eight key molecular properties. We validate our approach through rigorous experimentation on benchmark datasets (ESOL, FreeSolv, QM9) and demonstrate that the hybrid model consistently outperforms a strong classical BiLSTM baseline, achieving an $\mathbf{R}^{2}$ of up to 0.94 on QM9 and reducing inference time to seconds per molecule. Furthermore, we detail a complete production-ready pipeline, including SMILES tokenization, exploratory data analysis (EDA), handling of invalid inputs, and multiple deployment scenarios such as REST API integration for LIMS/ERP systems, active learning loops, and large-scale batch processing on cloud infrastructure. This work establishes a scalable and robust framework for integrating quantum computing into real-world cheminformatics workflows, offering a significant step toward quantumaccelerated drug design.

International Conference on Industrial Engineering, Applications and Manufacturing (ICIEAM)•May 18, 2026•0 citations

Quantum–Classical Neural Networks with Variational Circuits for Molecular Docking in Drug Discovery

K. Kalaiselvi, G. Husna Khouser, Kavitha A K +3 more

This work aims to propose a Quantum-Classical Neural Network with Variational quantum circuit (QCNN-VQC) to improve the accuracy of molecular docking in drug discovery. The model combines the classical feature extraction framework with quantum representations and energy-based optimisation to simulate intricate protein-ligand interactions. The molecular features are initially encoded into quantum states by first a standard neural network and then by encoding them into quantum states, where non-linear correlations and entanglement effects are modeled by variational circuits. An optimization strategy is used, that is quantum-inspired to achieve the minimum docking energy and find stable binding conformations. The experimental analysis of molecular docking datasets reveals that the proposed model achieves an accuracy of 91.2% compared to the classical neural networks (78.5%), and deep learning models (82.3%). The model also has a lower RMSE of 0.38 and higher R2score of 0.89 which means that it predicts better. The results of energy minimization indicate that the docking energy is greatly reduced, which proves the increased binding stability. The hybrid model is slightly more expensive to compute but it has competitive inference time. In general, QCNN VQC architecture offers a scalable and efficient drug discovery system; it can be optimally applied to quantum optimization in conjunction with deep learning and can result in a better prediction and strong molecular interaction modeling.

International Conference on Cognitive Computing and Networking Systems (ICC-CNS)•Jun 1, 2026•0 citations

A Critical Benchmark of Hybrid Quantum-Classical Graph Neural Networks for Molecular Property Prediction: Revealing Performance Bottlenecks in Current Architectures

Rakesh Kalshetty, Sreenivasa Manish, Shashank Kotagi +1 more

Hybrid quantum-classical neural networks (HQCNNs) represent a promising but largely unproven paradigm for enhancing molecular property prediction in drug discovery. Despite growing interest and optimistic claims in recent literature, rigorous benchmarks comparing these hybrid architectures against strong classical baselines remain scarce. This work implements and systematically evaluates a representative HQCNN architecture against its classical equivalent using standardized molecular datasets (QM9 and ZINC-250K) within a reproducible, multi-seed experimental framework. Contrary to optimistic expectations, our results reveal that the hybrid model consistently underperforms the classical baseline, showing a 49% increase in MAE on QM9 (1.0834 vs 0.7256) and a devastating 107% degradation on ZINC (1.4006 vs 0.6755), with R2values dropping by over 80% on both datasets. Through detailed analysis, we identify fundamental challenges including information bottlenecks during quantum encoding and difficult optimization landscapes in variational quantum circuits as primary causes of performance degradation. This work provides a crucial, datadriven reality check for the field, demonstrating that current “plug-and-play” quantum layer approaches may be insufficient for practical quantum advantages. All experimental code and data are publicly released to enable community replication and investigation of more sophisticated quantum-native architectures.

International Conference on Computation System and Information Technology for Sustainable Solutions (CSITSS)•Nov 20, 2025•0 citations

Quantum Machine Learning for Drug Discovery: From Molecular Descriptors to Explainable Quantum Pharmacology

Volkan Erol

Recent advances in quantum machine learning (QML) have opened new pathways for accelerating early-stage drug discovery through molecular representation in Hilbert space [1]–[3]. In this work, we present a hybrid quantum–classical framework that integrates quantum kernel estimation and variational quantum neural networks (QNNs) for ligand–target binding prediction [4], [5].A synthetic dataset reflecting the statistical behavior of the BindingDB database [6] was constructed to evaluate quantum descriptors and kernel performance under controlled conditions. The proposed quantum feature maps translate seven key molecular descriptors—molecular weight (MW), logP, hydrogen bond donors (HBD), acceptors (HBA), rotatable bonds (RB), aromatic rings (AR), and topological polar surface area (TPSA)—into entangled qubit states [7], [8].Comparative analyses with classical baselines (SVR, Random Forest, and deep neural networks) revealed that quantum embeddings achieve competitive predictive accuracy (RMSE ≈ 0.06) with improved stability under bootstrap resampling [9]. Quantum kernel alignment and sensitivity studies demonstrated that aromaticity and polarity jointly determine the representational power of QML models [10].Beyond performance, we emphasize Explainable Quantum Pharmacology (EQP)—a paradigm in which interpretability, reproducibility, and physicochemical causality are as essential as accuracy [11].Our findings establish a reproducible, interpretable, and computationally efficient foundation for hybrid QML pipelines in molecular modeling, paving the way for next-generation AI-driven drug discovery.

•Oct 10, 2025•0 citations

Quantum Machine Learning Algorithms for Drug Discovery and Molecular Property Prediction

Dr.H. Shaheen

Quantum machine learning (QML) has been demonstrated to have great potential in revolutionizing the process of drug discovery by dealing with the problem of high computational complexity of molecular simulations. Conventional computational techniques are not very effective in predicting the properties of molecules and pharmaceutical activity because the simulation of large molecules is too complex. This paper will discuss how QML algorithms can be used, specifically variational quantum circuits and quantum kernel methods, to improve the predictability of molecular properties and accelerate the process of drug discovery. To enhance the prediction accuracy, the research use quantum-enhanced feature extraction together with classical machine learning technologies. Research methodology is applied to datasets of molecular structure and biological activity in order to provide a more useful model to learn about how molecular features relate to biological outcomes using quantum machine learning models. These results suggest that it is 15 % more accurate in prediction and 20 % faster in computing high-dimensional molecular simulations compared to standard machine learning algorithms. The efficiency of the QML-based method is statistically proven with an accuracy 89%, precision 87%, and an F1-score of 0.91. The results point to the possible ability of QML to decrease the time and computational resources spent on the exploration of drug discovery, providing a new direction for the improvement of molecular property prediction. The study is a contribution to the emerging area of QML in pharmaceutical use and demonstrates that it can simplify drug discovery and enhance the accuracy with which predictions are made. The paper demonstrates that QML may produce a significant impact on the drug development process by simulating the molecular properties faster, more effectively, and more accurately.

International Academic Journal of Innovative Research•Mar 11, 2026•3 citations
Finding drug-like molecules is a time- and money-consuming task that requires virtual screening techniques capable of accurately representing non-linear intermolecular relationships. Classical ML models usually consider molecular graphs or SMILES sequences, but cannot jointly exploit both structural and sequential information, let alone simultaneously. Of greater importance, numerous deep learning methods are hindered by poor generalisation, black-box predictions, and inadequate interpretability, reducing their feasibility for application in real-life drug discovery pipelines. In this paper, we present QDrugDiscoverAI, a hybrid quantum–classical deep learning framework for predicting molecular properties and optimising molecules to overcome these challenges. We present a framework for multimodal molecular representation learning that combines graph attention networks and transformer-based sequence encoders with variational quantum circuits to increase expressive capacity within a single architecture. It implements a dual-stream representation-learning mechanism with a multimodal feature fusion layer. It includes an explainability module that uses attention weights and SHAP values to identify substructures that contribute to model predictions and enhance interpretability. Moreover, QDrugDiscoverAI also includes a quantum–assisted reinforcement-learning module for a molecule-optimisation workflow, enabling more efficient exploration of the chemical design space while leveraging the controllability of quantum simulation. The experiments on three benchmark datasets, i.e., Lipophilicity, HIV, and BBBP, show improvements of 12.4%, 9.6%, and 11.1% in accuracy, AUC, and F1-score, respectively, over the matched classical and unimodal baselines. Quantitative evaluation of quantum components and fusion strategies is also conducted through ablation studies to demonstrate their roles further. In summary, the framework proposed serves as a systematic integration of interpretable hybrid learning, showing one way it could be organised to become increasingly efficient, and demonstrating the advantage of using quantum-simulated components to enhance classical deep learning models for exploration and predictive performance in drug discovery workflows. The implementation code and supporting scripts for the proposed QDrugDiscoverAI framework are publicly available at: https://github.com/Sripada-RamaSree/QuantumDrugAI
The pharmaceutical industry faces mounting challenges in drug discovery, where exploring a chemical space exceeding 10 60 possible compounds remains computationally prohibitive. Traditional in-silico screening approaches struggle to capture the quantum mechanical interactions that determine molecular behavior. To overcome these limitations, this study introduces a hybrid quantum–classical machine learning framework that uniquely integrates molecular graph theory with quantum-enhanced learning for accelerated drug discovery. Using the QM9 benchmark dataset containing 133,885 molecules of low-to-medium structural complexity, we extract Laplacian eigenvalue spectra as topological descriptors that preserve both connectivity and electronic information. These features are jointly processed by Random Forest (RF), Support Vector Machine (SVM), and a Variational Quantum Classifier (VQC) in a weighted ensemble architecture designed for balanced generalization. The Quantum Graph Neural Network (QGNN) component achieves 97.5% accuracy, while the hybrid ensemble attains 100.0% accuracy, confirming strong predictive reliability. Although quantum training requires roughly 3.2× longer computation, it captures high-dimensional correlations that classical methods overlook. Overall, the proposed framework bridges the gap between theoretical quantum computing and practical pharmaceutical modeling, providing a scalable, physics-inspired pathway toward intelligent molecular screening and next-generation drug discovery systems.
The prediction of molecular properties from SMILES strings is a cornerstone of modern drug discovery and materials science, yet traditional computational methods often face a trade-off between accuracy and speed. This paper presents a comprehensive hybrid quantum-classical architecture that synergistically combines a Bidirectional Long Short-Term Memory (BiLSTM) network with a variational quantum circuit (VQC) to perform multi-task regression on molecular properties. Our system introduces a novel quantum feature layer, implemented in PennyLane and integrated with PyTorch, which employs data reuploading and configurable entanglement patterns (linear, full, pairwise) to generate expressive quantum descriptors. These descriptors are concatenated with classical features and fed into a regression head, enabling the simultaneous prediction of eight key molecular properties. We validate our approach through rigorous experimentation on benchmark datasets (ESOL, FreeSolv, QM9) and demonstrate that the hybrid model consistently outperforms a strong classical BiLSTM baseline, achieving an R2\mathbf{R}^{2}R2 of up to 0.94 on QM9 and reducing inference time to seconds per molecule. Furthermore, we detail a complete production-ready pipeline, including SMILES tokenization, exploratory data analysis (EDA), handling of invalid inputs, and multiple deployment scenarios such as REST API integration for LIMS/ERP systems, active learning loops, and large-scale batch processing on cloud infrastructure. This work establishes a scalable and robust framework for integrating quantum computing into real-world cheminformatics workflows, offering a significant step toward quantumaccelerated drug design.
This work aims to propose a Quantum-Classical Neural Network with Variational quantum circuit (QCNN-VQC) to improve the accuracy of molecular docking in drug discovery. The model combines the classical feature extraction framework with quantum representations and energy-based optimisation to simulate intricate protein-ligand interactions. The molecular features are initially encoded into quantum states by first a standard neural network and then by encoding them into quantum states, where non-linear correlations and entanglement effects are modeled by variational circuits. An optimization strategy is used, that is quantum-inspired to achieve the minimum docking energy and find stable binding conformations. The experimental analysis of molecular docking datasets reveals that the proposed model achieves an accuracy of 91.2% compared to the classical neural networks (78.5%), and deep learning models (82.3%). The model also has a lower RMSE of 0.38 and higher R2score of 0.89 which means that it predicts better. The results of energy minimization indicate that the docking energy is greatly reduced, which proves the increased binding stability. The hybrid model is slightly more expensive to compute but it has competitive inference time. In general, QCNN VQC architecture offers a scalable and efficient drug discovery system; it can be optimally applied to quantum optimization in conjunction with deep learning and can result in a better prediction and strong molecular interaction modeling.
Hybrid quantum-classical neural networks (HQCNNs) represent a promising but largely unproven paradigm for enhancing molecular property prediction in drug discovery. Despite growing interest and optimistic claims in recent literature, rigorous benchmarks comparing these hybrid architectures against strong classical baselines remain scarce. This work implements and systematically evaluates a representative HQCNN architecture against its classical equivalent using standardized molecular datasets (QM9 and ZINC-250K) within a reproducible, multi-seed experimental framework. Contrary to optimistic expectations, our results reveal that the hybrid model consistently underperforms the classical baseline, showing a 49% increase in MAE on QM9 (1.0834 vs 0.7256) and a devastating 107% degradation on ZINC (1.4006 vs 0.6755), with R2values dropping by over 80% on both datasets. Through detailed analysis, we identify fundamental challenges including information bottlenecks during quantum encoding and difficult optimization landscapes in variational quantum circuits as primary causes of performance degradation. This work provides a crucial, datadriven reality check for the field, demonstrating that current “plug-and-play” quantum layer approaches may be insufficient for practical quantum advantages. All experimental code and data are publicly released to enable community replication and investigation of more sophisticated quantum-native architectures.
Recent advances in quantum machine learning (QML) have opened new pathways for accelerating early-stage drug discovery through molecular representation in Hilbert space [1]–[3]. In this work, we present a hybrid quantum–classical framework that integrates quantum kernel estimation and variational quantum neural networks (QNNs) for ligand–target binding prediction [4], [5].A synthetic dataset reflecting the statistical behavior of the BindingDB database [6] was constructed to evaluate quantum descriptors and kernel performance under controlled conditions. The proposed quantum feature maps translate seven key molecular descriptors—molecular weight (MW), logP, hydrogen bond donors (HBD), acceptors (HBA), rotatable bonds (RB), aromatic rings (AR), and topological polar surface area (TPSA)—into entangled qubit states [7], [8].Comparative analyses with classical baselines (SVR, Random Forest, and deep neural networks) revealed that quantum embeddings achieve competitive predictive accuracy (RMSE ≈ 0.06) with improved stability under bootstrap resampling [9]. Quantum kernel alignment and sensitivity studies demonstrated that aromaticity and polarity jointly determine the representational power of QML models [10].Beyond performance, we emphasize Explainable Quantum Pharmacology (EQP)—a paradigm in which interpretability, reproducibility, and physicochemical causality are as essential as accuracy [11].Our findings establish a reproducible, interpretable, and computationally efficient foundation for hybrid QML pipelines in molecular modeling, paving the way for next-generation AI-driven drug discovery.
Quantum machine learning (QML) has been demonstrated to have great potential in revolutionizing the process of drug discovery by dealing with the problem of high computational complexity of molecular simulations. Conventional computational techniques are not very effective in predicting the properties of molecules and pharmaceutical activity because the simulation of large molecules is too complex. This paper will discuss how QML algorithms can be used, specifically variational quantum circuits and quantum kernel methods, to improve the predictability of molecular properties and accelerate the process of drug discovery. To enhance the prediction accuracy, the research use quantum-enhanced feature extraction together with classical machine learning technologies. Research methodology is applied to datasets of molecular structure and biological activity in order to provide a more useful model to learn about how molecular features relate to biological outcomes using quantum machine learning models. These results suggest that it is 15 % more accurate in prediction and 20 % faster in computing high-dimensional molecular simulations compared to standard machine learning algorithms. The efficiency of the QML-based method is statistically proven with an accuracy 89%, precision 87%, and an F1-score of 0.91. The results point to the possible ability of QML to decrease the time and computational resources spent on the exploration of drug discovery, providing a new direction for the improvement of molecular property prediction. The study is a contribution to the emerging area of QML in pharmaceutical use and demonstrates that it can simplify drug discovery and enhance the accuracy with which predictions are made. The paper demonstrates that QML may produce a significant impact on the drug development process by simulating the molecular properties faster, more effectively, and more accurately.